Novel benzothiazole derivatives as multitargeted-directed ligands for the treatment of Alzheimer’s disease

References

• Kamer AR, Craig RG, Niederman R, Fortea J, de Leon MJ. Periodontal disease as a possible cause for Alzheimer’s disease. Periodontol 2000. 2020;83(1):242–271.
   PubMed Web of Science ®Google Scholar
• Lopes FB, Aranha CMSQ, Fernandes JPS. Histamine H3 receptor and cholinesterases as synergistic targets for cognitive decline: Strategies to the rational design of multitarget ligands. Chem Biol Drug Des. 2021;98(2):212–225.
   PubMed Web of Science ®Google Scholar
• Abeysinghe AADT, Deshapriya RDUS, Udawatte C. Alzheimer’ s disease; a review of the pathophysiological basis and therapeutic interventions. Life Sci. 2020;256:117996.
   PubMed Web of Science ®Google Scholar
• Sharma K. Cholinesterase inhibitors as Alzheimer’s therapeutics. Mol Med Rep. 2019;20(2):1479–1487.
   PubMed Web of Science ®Google Scholar
• Kumar B, Thakur A, Dwivedi AR, Kumar R, Kumar V. Multi-target-directed ligands as an effective strategy for the treatment of Alzheimer’s disease. Curr Med Chem. 2022;29(10):1757–1803.
   PubMed Web of Science ®Google Scholar
• Pasieka A, Panek D, Malawska B. Multifunctional ligand approach: search for effective therapy against Alzheimer’s disease. Exon Publications. 2020:181–203.
   Google Scholar
• Nikolic K, Mavridis L, Bautista-Aguilera OM, Marco-Contelles J, Stark H, do Carmo Carreiras M, Rossi I, Massarelli P, Agbaba D, Ramsay RR, et al. Predicting targets of compounds against neurological diseases using cheminformatic methodology. J Comput Aided Mol Des. 2015;29(2):183–198.
   PubMed Web of Science ®Google Scholar
• de Freitas Silva M, Dias KST, Gontijo VS, Ortiz CJC, Viegas C. Jr Multi-target directed drugs as a modern approach for drug design towards Alzheimer’s disease: an update. Curr Med Chem. 2018;25(29):3491–3525.
   PubMed Web of Science ®Google Scholar
• Maramai S, Benchekroun M, Gabr MT, Yahiaoui S. Multitarget therapeutic strategies for Alzheimer’s disease: review on emerging target combinations. Biomed Res Int. 2020;2020.
   PubMed Web of Science ®Google Scholar
• Mishra P, Kumar A, Panda G. Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer’s disease (1998–2018). Bioorganic Med Chem. 2019;27(6):895–930.
   PubMed Web of Science ®Google Scholar
• Khanfar MA, Affini A, Lutsenko K, Nikolic K, Butini S, Stark H. Multiple targeting approaches on histamine H3 receptor antagonists. Front Neurosci. 2016;10:201.
   PubMed Web of Science ®Google Scholar
• Ghamari N, Zarei O, Arias-Montaño J-A, Reiner D, Dastmalchi S, Stark H, Hamzeh-Mivehroud M. Histamine H3 receptor antagonists/inverse agonists: where do they go? Pharmacol Ther. 2019;200:69–84.
   PubMed Web of Science ®Google Scholar
• Harwell V, Fasinu PS. Pitolisant and other histamine-3 receptor antagonists—an update on therapeutic potentials and clinical prospects. Medicines. 2020;7(9):55.
   Google Scholar
• Bautista-Aguilera ÓM, Hagenow S, Palomino-Antolin A, Farré-Alins V, Ismaili L, Joffrin P-L, Jimeno ML, Soukup O, Janočková J, Kalinowsky L, et al. Multitarget-directed ligands combining cholinesterase and monoamine oxidase inhibition with histamine H3R antagonism for neurodegenerative diseases. Angew Chem Int Ed Engl. 2017;56(41):12765–12769.
   PubMed Web of Science ®Google Scholar
• Godyń J, Zaręba P, Łażewska D, Stary D, Reiner-Link D, Frank A, Latacz G, Mogilski S, Kaleta M, Doroz-Płonka A, et al. Cyanobiphenyls: novel H3 receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer’s disease. Bioorg Chem. 2021;114:105129.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hu Y, Lu X, Yang H, Li Q, Du C, Chen Y, Hong KH, Sun H. Discovery of a selective 6-hydroxy-1, 4-diazepan-2-one containing butyrylcholinesterase inhibitor by virtual screening and MM-GBSA rescoring. Dose Response. 2020;18(2):1559325820938526.
   Web of Science ®Google Scholar
• Darvesh S. Butyrylcholinesterase as a diagnostic and therapeutic target for Alzheimer’s disease. Curr Alzheimer Res. 2016;13(10):1173–1177.
   PubMed Web of Science ®Google Scholar
• El-Sayed NA-E, Farag AE-S, Ezzat MAF, Akincioglu H, Gülçin İ, Abou-Seri SM. Design, synthesis, in vitro and in vivo evaluation of novel pyrrolizine-based compounds with potential activity as cholinesterase inhibitors and anti-Alzheimer’s agents. Bioorg Chem. 2019;93:103312.
   PubMed Web of Science ®Google Scholar
• Jończyk J, Lodarski K, Staszewski M, Godyń J, Zaręba P, Soukup O, Janockova J, Korabecny J, Sałat K, Malikowska-Racia N, et al. Search for multifunctional agents against Alzheimer’s disease among non-imidazole histamine H3 receptor ligands. In vitro and in vivo pharmacological evaluation and computational studies of piperazine derivatives. Bioorg Chem. 2019;90:103084.
   PubMed Web of Science ®Google Scholar
• Gill RK, Rawal RK, Bariwal J. Recent advances in the chemistry and biology of benzothiazoles. Arch Pharm. 2015;348(3):155–178.
   PubMed Web of Science ®Google Scholar
• Sharma PC, Sinhmar A, Sharma A, Rajak H, Pathak DP. Medicinal significance of benzothiazole scaffold: an insight view. J Enzyme Inhib Med Chem. 2013;28(2):240–266.
   PubMed Web of Science ®Google Scholar
• Keri RS, Patil MR, Patil SA, Budagumpi SA. comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry. Eur J Med Chem. 2015;89:207–251.
   PubMed Web of Science ®Google Scholar
• Pathak N, Rathi E, Kumar N, Kini SG, Rao CM. A review on anticancer potentials of benzothiazole derivatives. Mini Rev Med Chem. 2020;20(1):12–23.
   PubMed Web of Science ®Google Scholar
• Rouf A, Tanyeli C. Bioactive thiazole and benzothiazole derivatives. Eur J Med Chem. 2015;97:911–927.
   PubMed Web of Science ®Google Scholar
• Aboushady Y, Gabr M, ElHady AK, Salah M, Abadi AH, Wilms G, Becker W, Abdel-Halim M, Engel M. Discovery of hydroxybenzothiazole urea compounds as multitargeted agents suppressing major cytotoxic mechanisms in neurodegenerative diseases. ACS Chem Neurosci. 2021;12(22):4302–4318.
   PubMed Web of Science ®Google Scholar
• AlNajjar YT, Gabr M, ElHady AK, Salah M, Wilms G, Abadi AH, Becker W, Abdel-Halim M, Engel M. Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects. Eur J Med Chem. 2022;227:113911.
   PubMed Web of Science ®Google Scholar
• Salah M, Abdel-Halim M, Engel M. Design and synthesis of conformationally constraint Dyrk1A inhibitors by creating an intramolecular H-bond involving a benzothiazole core. Medchemcomm. 2018;9(6):1045–1053.
   PubMed Web of Science ®Google Scholar
• Rosales Hernández MC, Fragoso Morales LG, Correa Basurto J, Olvera Valdez M, García Báez EV, Román Vázquez DG, Anaya García AP, Cruz A. In silico and in vitro studies of benzothiazole-isothioureas derivatives as a multitarget compound for Alzheimer’s disease. IJMS. 2022;23(21):12945.
   Google Scholar
• Matthews DC, Mao X, Dowd K, Tsakanikas D, Jiang CS, Meuser C, Andrews RD, Lukic AS, Lee J, Hampilos N, et al. Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer’s disease. Brain. 2021;144(12):3742–3755.
   PubMedGoogle Scholar
• Behl T, Kaur D, Sehgal A, Singh S, Sharma N, Zengin G, Andronie-Cioara FL, Toma MM, Bungau S, Bumbu AG, et al. Role of monoamine oxidase activity in Alzheimer’s disease: an insight into the therapeutic potential of inhibitors. Molecules. 2021;26(12):3724.
   PubMed Web of Science ®Google Scholar
• Łażewska D, Bajda M, Kaleta M, Zaręba P, Doroz-Płonka A, Siwek A, Alachkar A, Mogilski S, Saad A, Kuder K, et al. Rational design of new multitarget histamine H3 receptor ligands as potential candidates for treatment of Alzheimer’s disease. Eur J Med Chem. 2020;207:112743.
   PubMed Web of Science ®Google Scholar
• Lipp R, Stark H, Schunack W. Pharmacochemistry of H3-receptors. 1992:57–72. https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Pharmacochemistry+of+H3-receptors+stark&btnG=
   Google Scholar
• Sylvain C, Maikel W, Patrice T, Rob L, Iwan JPE. Histamine H3 receptor antagonist reach out for the clinics. Drug Disc Today. 2005;10:1613–1627.
   PubMed Web of Science ®Google Scholar
• Wingen K, Stark H. Scaffold variations in amine warhead of histamine H3 receptor antagonists. Drug Discov Today Technol. 2013;10(4):e483–e489.
   PubMedGoogle Scholar
• Meier G, Apelt J, Reichert U, Grassmann S, Ligneau X, Elz S, Leurquin F, Ganellin CR, Schwartz JC, Schunack W, et al. Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists. Eur J Pharm Sci. 2001;13(3):249–259.
   PubMed Web of Science ®Google Scholar
• Walczynski K, Guryn R, Zuiderveld OP, Timmerman H. Non‐imidazole histamine H3 ligands, part 2: new 2‐substituted benzothiazoles as histamine H3 antagonists. Arch Pharm Pharm Med Chem. 1999;332(11):389–398.
   PubMed Web of Science ®Google Scholar
• Walczyński K, Guryn R, Zuiderveld OP, Timmerman H. Non-imidazole histamine H3 ligands. Part I. Synthesis of 2-(1-piperazinyl)-and 2-(hexahydro-1H-1, 4-diazepin-1-yl) benzothiazole derivatives as H3-antagonists with H1 blocking activities. Farm. 1999;54(10):684–694.
   Google Scholar
• Bordi F, Mor M, Morini G, et al. QSAR study on H3-receptor affinity of benzothiazole derivatives of thioperamide. Farm. 1994;49:153–166.
   Google Scholar
• Löwik DWPM, Tisi LC, Murray JAH, Lowe CR. Synthesis of 6-hydroxybenzothiazole-2-carboxylic acid. Synthesis. 2001;2001(12):1780–1783.
   Google Scholar
• Ghosh AK, Shahabi D. Synthesis of amide derivatives for electron deficient amines and functionalized carboxylic acids using EDC and DMAP and a catalytic amount of HOBt as the coupling reagents. Tetrahedron Lett. 2021;63(152719):152719.
   PubMedGoogle Scholar
• Wang K, Yu L, Shi J, Liu W, Sang Z. Multifunctional indanone–chalcone hybrid compounds with anti-β-amyloid (Aβ) aggregation, monoamine oxidase B (MAO-B) inhibition and neuroprotective properties against Alzheimer’s disease. Med Chem Res. 2019;28(11):1912–1922.
   Web of Science ®Google Scholar
• Cai Z. Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer’s disease. Mol Med Rep. 2014;9(5):1533–1541.
   PubMed Web of Science ®Google Scholar
• Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, Katritch V, Abagyan R, Cherezov V, Liu W, Han GW, et al. Structure of the human histamine H 1 receptor complex with doxepin. Nature. 2011;475(7354):65–70.
   PubMed Web of Science ®Google Scholar
• Jończyk J, Malawska B, Bajda M. Hybrid approach to structure modeling of the histamine H3 receptor: Multi-level assessment as a tool for model verification. PLOS One. 2017;12(10):e0186108.
   PubMed Web of Science ®Google Scholar
• Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2005;2(4):541–553.
   PubMedGoogle Scholar
• Darwish SS, Abdel-Halim M, Salah M, Abadi AH, Becker W, Engel M. Development of novel 2, 4-bispyridyl thiophene–based compounds as highly potent and selective Dyrk1A inhibitors. Part I: benzamide and benzylamide derivatives. Eur J Med Chem. 2018;157:1031–1050.
   PubMed Web of Science ®Google Scholar
• Yung-Chi C, Prusoff WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973;22(23):3099–3108.
   PubMed Web of Science ®Google Scholar
• Pisani L, Catto M, De Palma A, Farina R, Cellamare S, Altomare CD. Discovery of potent dual binding site acetylcholinesterase inhibitors via homo‐and heterodimerization of coumarin‐based moieties. ChemMedChem. 2017;12(16):1349–1358.
   PubMed Web of Science ®Google Scholar
• Pisani L, Iacobazzi RM, Catto M, Rullo M, Farina R, Denora N, Cellamare S, Altomare CD. Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors. Eur J Med Chem. 2019;161:292–309.
   PubMed Web of Science ®Google Scholar